Press ReleaseNicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039 October 29, 2020 – release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the European Patent Office has granted a formulation patent for NCX 470, extending the European exclusivity to 2039. The equivalent U.S. patent has already been granted, and NCX 470 is also covered by granted composition of matter patents. Gavin Spencer, Chief Business Officer at Nicox, said: “We are pleased that our formulation patent for NCX 470 has been granted in Europe, following the U.S. grant earlier in the year. This strengthens our competitive position and provides further protection of this potential best-in-class product candidate for the lowering of intraocular pressure as we continue Phase 3 development and move it towards commercialization.” NCX 470, Nicox’s lead clinical product candidate, is a novel second-generation nitric oxide (NO)-donating bimatoprost analog for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is currently being evaluated in the Mont Blanc Phase 3 clinical trial which was initiated in the U.S. in June 2020 with top-line results currently expected in Q4 2021. A second Phase 3 trial, Denali, is expected to start by the end of 2020, and will include clinical sites in both the U.S. and China, with the majority of the patients to be recruited in the U.S. NCX 470 is exclusively licensed to Ocumension Therapeutics for the Chinese, Korean and South East Asian markets. The Denali trial is jointly funded by Nicox and Ocumension.About NCX 470NCX 470 is a novel, potential best-in-class, second generation nitric oxide (NO)-donating bimatoprost analog in development to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Glaucoma is a group of ocular diseases in which the optic nerve is injured, leading to peripheral and, ultimately, central visual field loss and it can eventually lead to blindness if not treated. It is frequently linked to abnormally high IOP (~90% of patients) due to blockage or malfunction of the eye’s aqueous humor drainage system in the front of the eye. In 2019, worldwide sales of treatments targeting glaucoma were over $6.0 billion out of a $21.9 billion worldwide market for ophthalmic drugs. NCX 470 is designed to release both bimatoprost and NO following instillation into the eye. Bimatoprost, marketed under the brand name LUMIGAN® by Allergan, Inc., is one of the leading products in the class of prostaglandin analogs, the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension. About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.H.C. Wainwright & Co Yi Chen New York, U.S.Oppenheimer & Co Hartaj Singh New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 email@example.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 firstname.lastname@example.orgMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 email@example.comForward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website (www.nicox.com).Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Attachment EN_NCX 470 EUFormulation Patent Approval PR_20201029_F1 (1)
Amsterdam/’s-Hertogenbosch, the Netherlands, 29 October 2020 Quarterly result in line with second quarter of the yearClient assets added 3% to €106.3 billion and AuM 3% to €92.0 billionNet AuM inflow of €1.4 billion at Private Banking and Asset ManagementLimited addition to loan loss provisions, reflecting our wealth management profileCapital ratio increases to 24.9% Van Lanschot Kempen today released its trading update for the third quarter of 2020. Constant Korthout, Van Lanschot Kempen’s Chief Financial & Risk Officer, said: “The current circumstances around Covid-19 remain exceptional and we’re seeing the impact of the virus return and increase all around us. At the same time, we note that the third quarter was a good one financially for most of our clients. The low risk exposure in our loan portfolio and resultant minor addition to our loan loss provisions have once again proven the robustness of our wealth management model. Over the past few months, we have stuck to the cost-saving measures announced previously, and the outcomes show that we have costs under control. We’re pleased with our solid results in the third quarter.” Client assets increased by €2.9 billion to €106.3 billion in the quarter. Assets under management (AuM) were up €2.8 billion to €92.0 billion on net inflows of €1.4 billion combined with a positive market performance of €1.4 billion. Private Banking once again reported net AuM inflows in the third quarter of €0.3 billion (YTD €0.8 billion). These net inflows – both in the Netherlands and in Belgium – reflect our clients’ continued willingness to invest. Meanwhile, Asset Management recorded net inflows of €1.1 billion (YTD €4.9 billion), and some €1.4 billion was added to fiduciary management, mainly on the back of the new €1.0 billion mandate for Stichting Pensioenfonds Grontmij. Investment strategies, by contrast, fell in the quarter, in part caused by funds being discontinued. Our Corporate Finance & Equity Capital Markets team had another good quarter, completing deals in all niche markets in which they operate. Within Life Sciences, we were involved in CureVac’s IPO on America’s Nasdaq market and the secondary offering of Kojamo shares in the real estate sector. Meanwhile, Unifiedpost in Belgium was our first IPO in the fintech sector. In August, we announced the next step in our growth strategy by acquiring Hof Hoorneman Bankiers. We have applied for a declaration of no objection from our regulator and are awaiting their approval. To further optimise our capital position and simplify our legal structure, we are currently investigating the possibility of merging our holding company Van Lanschot Kempen NV with our operating company Van Lanschot Kempen Wealth Management NV in 2021. Our current capital position remains strong and our CET 1 ratio amounts to 24.9% (excluding retained earnings). As previously announced, and taking heed of the ECB’s and DNB’s advice, we will not pay out our 2019 dividend before January 2021. This €59.4 million dividend is reserved for our shareholders on our balance sheet and is not included in our capital ratios. FINANCIAL CALENDAR25 February 2021 Publication of 2020 annual results Media Relations: + 31 20 354 45 85; firstname.lastname@example.org Investor Relations: +31 20 354 45 90; email@example.com About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager operating under the Van Lanschot, Kempen and Evi brand names, is active in Private Banking, Asset Management and Merchant Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737. For more information, please visit vanlanschotkempen.com Disclaimer and cautionary note on forward-looking statements This press release may contain forward-looking statements on future events and developments. These forward-looking statements are based on the current insights, information and assumptions of Van Lanschot Kempen’s management about known and unknown risks, developments and uncertainties. Forward-looking statements do not relate strictly to historical or current facts and are subject to such risks, developments and uncertainties which by their very nature fall outside the control of Van Lanschot Kempen and its management. Actual results, performances and circumstances may differ considerably from these forward-looking statements as a result of risks, developments and uncertainties relating to, but not limited to, (a) income growth, (b) costs, (c) the macroeconomic and business climate, (d) political and market trends, (e) interest rates and currency exchange rates, (f) behaviour of clients, competitors, investors and counterparties, (g) the implementation of Van Lanschot Kempen’s strategy, (h) actions taken by supervisory and regulatory authorities and private entities, (i) changes in law and taxation, (j) changes in ownership that could affect the future availability of capital, (k) changes in credit ratings and (l) evolution and economic and societal impact of the Covid-19 pandemic. Van Lanschot Kempen cautions that forward-looking statements in this press release are only valid on the specific dates on which they are expressed, and accepts no responsibility or obligation to revise or update any information, whether as a result of new information or for any other reason. The financial data in this press release have not been audited, unless specifically stated otherwise. This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action. Elements of this press release contain information about Van Lanschot Kempen NV and/or Van Lanschot NV within the meaning of Article 7(1) to (4) of EU Regulation No. 596/2014. This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof. Attachment Press release_Trading update Q3 2020
ALLSCHWIL, Switzerland, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic breast cancer. A total of 411 patients have been recruited, including 323 in the third line cohort and 88 patients in the second line cohort. Although recruitment is closed, Polyphor will allow all patients that have already registered for the study to be enrolled. This may increase the final number of patients enrolled in the study to approximately 430. As previously communicated, data on the key primary endpoint of FORTRESS, progression free survival (PFS) in the overall population, is planned for Q4 2021. An analysis of the objective response rate (ORR) in eligible patients in third and later lines of chemotherapy is planned for Q2 2021. “We are pleased to have completed recruitment in this important study in a timely manner. Balixafortide is currently the only potent blocker of CXCR4, a key molecule involved in tumor growth and metastasis, in Phase 3 clinical development for a solid tumor and as such, it has significant potential to improve the lives of patients,” said Dr. Frank Weber, Chief Medical and Development Officer at Polyphor. “We would like to take this opportunity to thank first and foremost the patients, but also the investigators and the local staff as well as our employees for their active participation in this study. This great effort has enabled us to complete the recruitment as planned, despite the difficulties caused by the current pandemic.” The FORTRESS study (POL6326-009) is an international, multicenter, randomized active-controlled, open-label Phase III trial which investigates the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, locally recurrent or metastatic breast cancer. Subject to the data, Polyphor may submit a filing for accelerated approval in the US based on the analysis of the ORR, confirmed by an independent blinded review, and of the associated durability of response. The full approval would be based on the magnitude of PFS on blinded independent review, supported by an overall survival trend favoring the balixafortide arm and a favorable risk-benefit profile. For more information about the POL6326-009 clinical trial of balixafortide, please visit www.clinicaltrials.gov (Identifier: NCT03786094) For further information please contact: For Investors: Hernan LevettChief Financial OfficerPolyphor Ltd.+41 61 567 16 00IR@polyphor.comMary-Ann ChangLifeSci AdvisorsTel: +44 7483 284 firstname.lastname@example.org For Media: Bernhard SchmidLifeSci Advisors+41 44 447 12 email@example.com About PolyphorPolyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com. DisclaimerThis press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Sanoma Corporation, Interim Report, 29 October 2020 at 8:30 EET Sanoma’s Interim Report January-September 2020: Strong performance: Net sales grew and operational EBIT improved This release is a summary of Sanoma’s Q3 2020 Interim Report. The complete report is attached to this release and is also available at sanoma.com. Q3 2020 The Group’s net sales grew to EUR 401 million (2019: 285). Net sales of Learning grew mainly driven by acquisitions, in particular Iddink, and strong comparable net sales development during the high season especially in Poland. Net sales of Media Finland declined slightly. The Group’s comparable net sales development was -2% (2019: -1%).Operational EBIT excl. PPA improved to EUR 111 million (2019: 78) driven by acquisitions, in particular Iddink, as well as good comparable earnings development in Learning.EBIT was EUR 267 million (2019: 69). Items affecting comparability (IACs) totalled EUR 161 million (2019: -7) and included a capital gain of EUR 165 million related to the divestment of Oikotie. PPA amortisations were EUR 6 million (2019: 2).Operational EPS was EUR 0.50 (2019: 0.32) and EUR 0.50 (2019: 0.39) including discontinued operations.EPS was EUR 1.49 (2019: 0.29) and EUR 1.50 (2019: 0.35) including discontinued operations.On 28 October, the Board of Directors decided the record date and payment date of the second dividend instalment of EUR 0.25 per share. The dividend record date is 30 October and the payment date 6 November.On 19 October, Sanoma announced the acquisition of Santillana Spain with an enterprise value of EUR 465 million.On 8 October, Sanoma published an updated Outlook for 2020.On 16 July, Sanoma announced and completed the divestment of Oikotie to Schibsted with an enterprise value of EUR 185 million. Q1-Q3 2020 The Group’s net sales grew to EUR 835 million (2019: 708) mainly as a result of the Iddink acquisition, while net sales development of Media Finland was adversely impacted by the coronavirus pandemic. The Group’s comparable net sales development was -6% (2019: -1%).Operational EBIT excl. PPA grew to EUR 156 million (2019: 133). Earnings improved in Learning mainly as a result of the Iddink acquisition, while declining in Media Finland.EBIT was EUR 291 million (2019: 112). IACs totalled EUR 151 million (2019: -15) and included a capital gain of EUR 165 million related to the divestment of Oikotie. PPA amortisations were EUR 17 million (2019: 6).Operational EPS was EUR 0.64 (2019: 0.51) and EUR 0.73 (2019: 0.73) including discontinued operations.EPS was EUR 1.59 (2019: 0.44) and EUR 1.67 (2019: 0.71) including discontinued operations.On 30 April, Sanoma completed the acquisition of Alma Media’s regional news media business in Finland with an enterprise value of EUR 115 million. The acquisition was announced on 11 February 2020.On 20 April, Sanoma completed the divestment of Sanoma Media Netherlands to DPG Media with an enterprise value of EUR 460 million. Outlook for 2020 (published on 8 October) In 2020, Sanoma expects that the Group’s reported net sales will be around EUR 1,050 million (2019: 913). The Group’s operational EBIT margin excluding PPA is expected to be around 14% (2019: 14.8%), which in this case means the margin is not expected to be below 13% or above 15%. The outlook is based on the assumption that the advertising market decline in Finland in 2020 will be between 15-20% compared to 2019. President and CEO Susan Duinhoven: ”Our business and financial performance was strong during the important third quarter, which is typically the high season of the learning business. Based on the improving performance we have experienced in the last months of the coronavirus pandemic, and the prospects that we see for the final quarter of the year, we were able to give an updated outlook for 2020 on 8 October. We expect reported net sales to be around EUR 1,050 million (2019: 913) and operational EBIT margin excl. PPA around 14% (2019: 14.8%), which is a relatively small adjustment compared to the around 15% margin outlook that we had given in the beginning of this year. I am very proud of and grateful for the agile, supportive and inventive way in which our teams across Sanoma have approached the exceptional challenge that the pandemic put to our customers and our business. Thanks to their hard work, our performance has been much stronger than we would have dared to hope for when the pandemic started, and we now have a good outlook for the full year. We have also progressed well on our strategic objectives. In July‒September, we again saw an increase in subscription sales for both news and entertainment. The number of subscriptions for the largest daily newspaper, Helsingin Sanomat, is now above 400,000, of which about one third are digital-only. Also, our VOD service Ruutu+ has reached more than 300,000 subscriptions. During the past months, our teams have been working hard with the integration of the regional news media business acquired at the end of April, and are proceeding as planned. After summer, the recovery in advertising sales, which were significantly impacted by the coronavirus pandemic in March-July, has accelerated and exceeded our earlier expectations. That being said, we believe that there continues to be significant uncertainty related to advertising demand in the coming months, which will most likely be seen next year as well. The third quarter is always an important one in the learning business, and this year we saw solid growth driven by curriculum renewals especially in Poland and to some extent also in the Netherlands. Teams across Sanoma Learning performed very well during this busy time of the year and under the continuing exceptional circumstances caused by the coronavirus pandemic especially in our distribution operations. Iddink was, for the first time, part of Sanoma Learning during the high season, and its business performance and integration have proceeded well and according to our plans. Last week, we announced the next major step on our learning growth path: the acquisition of Santillana Spain, a leading provider of learning content in Spain. This acquisition is a strong next step in Sanoma’s strategic transformation into a growing European learning company and a leading cross-media company in Finland. It will grow Learning’s share of our earnings (operational EBIT excl. PPA) from 55% to over 65% and further strengthen our cash flow generation capabilities. We see great potential in the Spanish market, related not only to the upcoming curriculum renewal expected to be implemented in 2022–23, but also to increasing digitalisation, which has been further stimulated by growing need for remote learning tools during the coronavirus pandemic. We are planning to use our experience in highly digitalised countries and our digital platforms developed over the past 10 years to accelerate the growth of Santillana Spain over time. The acquisition of Santillana Spain will not have an impact on our long-term strategy, financial targets or dividend policy. We want to continue our current growth strategy: aiming to grow our European learning business further through M&A in current operating countries or new markets, and to strengthen our media business in Finland in its chosen core businesses: news & feature, entertainment and B2B marketing solutions.” Key indicators for continuing operations EUR millionQ3 2020Q3 2019ChangeQ1-Q3 2020Q1-Q3 2019Change FY 2019Net sales401.1284.941%835.1707.718%913.3Operational EBIT excl. PPA 1)111.377.544%156.4133.118%135.2 Margin 1)27.7%27.2% 18.7%18.8% 14.8%EBIT266.569.1286%291.2112.3159%102.1Result for the period243.948.5402%260.273.2255%63.1 Operational EPS, EUR 2)0.500.3257%0.640.5124%0.49EPS, EUR1.490.29417%1.590.44261%0.38 Average number of employees (FTE) 4,2253,48521%3,567Number of employees at the end of the period (FTE) 4,2173,74013%3,953 Key indicators incl. continuing and discontinued operations 3) EUR millionQ3 2020Q3 2019ChangeQ1-Q3 2020Q1-Q3 2019Change FY 2019Result for the period244.359.2313%274.0116.6135%13.3 Free cash flow129.697.533%64.556.314%131.3 Equity ratio 48.5%33.8% 30.5%Net debt 234.2797.8-71%794.7Net debt / Adj. EBITDA 1.02.8-64%2.7 Operational EPS, EUR 2)0.500.3930%0.730.731%0.80EPS, EUR1.500.35323%1.670.71137%0.07Free cash flow per share, EUR0.790.6033%0.400.3514%0.81 1) Excluding IACs and purchase price allocation amortisations (PPAs)2) Excluding IACs3) In 2020 and 2019, discontinued operations include Sanoma Media Netherlands and certain minor subsidiaries acquired in 2019 and planned to be divested in the future. In Q1-Q3 2020, result of discontinued operations includes a capital loss of EUR 2 million (2019: 105) related to the divestment costs of Media Netherlands. Analyst and investor conference An analyst and investor webcast and teleconference will be held in English by the President and CEO Susan Duinhoven and CFO and COO Markus Holm at 11:00. The live webcast can be followed via https://sanoma.videosync.fi/2020-q3-results. To ask questions by phone during the live webcast, please join in 5–10 minutes prior to the starting time by dialing one of the following numbers: Finland: +358 9 8171 0310 Sweden: +46 8 5664 2651 United Kingdom: +44 33 3300 0804 United States: +1 631 913 1422 Confirmation code for the call is 58838770#. An on-demand replay of the webcast will be available shortly after the conference at www.sanoma.com/investors. Interview opportunities for media by Teams or by phone are available after the conference. Media representatives are asked to book interviews via Communications Director Marcus Wiklund, firstname.lastname@example.org. Additional information Kaisa Uurasmaa, Head of Investor Relations and CSR, tel. +358 40 560 5601 About Sanoma Sanoma is an innovative and agile learning and media company impacting the lives of millions every day. Our learning products and services enable teachers to develop the talents of every child to reach their full potential. We offer printed and digital course materials as well as digital learning and teaching platforms for primary, secondary and vocational education, and want to grow our business across Europe. Our Finnish media provide independent journalism and engaging entertainment also for generations to come. Our unique cross-media position offers the widest reach and tailored marketing solutions for our business partners. Today, we operate in eleven European countries and employ close to 4,500 professionals. In 2019, our net sales totalled 900m€ and our operational EBIT margin excl. PPA was 14.8%. Sanoma shares are listed on Nasdaq Helsinki. More information is available at www.sanoma.com. Attachment Sanoma Q3 2020 Interim Report
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 28 Oct 2020. Estimated NAV Euro SharesSterling SharesEstimated NAV€ 24.0422£ 21.2607Estimated MTD return 1.08 % 0.95 %Estimated YTD return 4.99 % 3.03 %Estimated ITD return 140.42 % 112.61 % NAV and returns are calculated net of management and performance fees Market information Euro SharesAmsterdam (AEX)London (LSE)Market Close€ 17.90N/APremium/discount to estimated NAV -25.55 %N/A Sterling SharesAmsterdam (AEX)London (LSE)Market CloseN/AGBX 1,500.00Premium/discount to estimated NAVN/A -29.45 % Transactions in own securities purchased into treasury Ordinary Shares Euro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/ARange of PriceN/AN/A Liquidity Enhancement AgreementEuro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/A BGHL Capital BGHL Ordinary SharesEuro SharesSterling SharesShares Outstanding 13,961,778 301,536Held in treasury 100,000N/AShares Issued 14,061,778 301,536 Estimated BG Fund NAV Class B Euro Shares (estimated)€ 199.4788 The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL. For further information please contact: Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : email@example.com The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities. This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States. You should always bear in mind that: all investment is subject to risk; results in the past are no guarantee of future results; the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice. This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice. Attachment BGHL Publication-28.10
Transamerica, Aegon’s business in the United States, has sold the Pyramid building complex which includes the Pyramid, 505 Sansome, the Redwood Park and other properties in the block bounded by Montgomery Street, Clay Street, Washington Street, and Sansome Street in San Francisco, to a joint venture led by Michael Shvo. Transamerica will continue to use the Pyramid as its logo and trademark. Transamerica will provide a mortgage loan supporting the property at commercial rates. The transaction will allow for a further diversification of the investment portfolio at favorable yields, therewith improving the risk profile of the Group.
Japanese automakers saw a 2.1% drop in global vehicles sales in September compared with a year earlier, the seventh straight month of declines, as the coronavirus pandemic continued to hurt demand even as factories and dealerships reopen. The country's seven major automakers, including Toyota Motor Corp and Nissan Motor Co, sold a combined 2.3 million vehicles last month, according to Reuters calculations based on sales data released by the companies on Thursday. The decline in monthly sales has, however, slowed significantly since a 50% slump in April as the Japanese car makers benefit from a rebound in demand, particularly in China, the world's biggest auto market.
Norway's Equinor wrote off $2.93 billion from the value of its assets after cutting its long-term oil price forecast on Thursday, betting the pandemic and a shift away from fossil fuels will have a lasting impact on markets. Including the asset write-off, Equinor posted a net loss of $2.12 billion in the third quarter. The energy major's adjusted earnings before interest and tax (EBIT) fell to $780 million in July-September from $2.59 billion in the same period of 2019, lagging the $1.03 billion predicted in a poll of 24 analysts compiled by Equinor.
Airbus said on Thursday it expected to reach cash breakeven in the fourth quarter, setting the first forward-looking target since the start of the coronavirus crisis after managing to stop bleeding cash in the third quarter.
Heavy rains and strong winds triggered by a typhoon hit Vietnam's key coffee growing region this week, posing a threat to the country's harvest, while the Indonesian market was tepid at the end of the harvest season, traders said on Thursday. Typhoon Molave, the most intense one to hit Vietnam this year, flooded low-lying areas in a key coffee-growing region and ripped some coffee cherries off the trees. Meanwhile, the Central Highlands, Vietnam's main coffee belt, is expected to see intermittent rainfall over the next 10 days, which may affect harvesting, as per the National Meteorological and Hydrological Center's forecast.
Nationals call for ANZ boycott after bank's push for net zero emissions. Bank says it will stop lending to its largest customers unless businesses have carbon transition plans
Thursday briefing: England’s south warned over case rises. Country in ‘critical stage’, says Imperial College study … Nigel Farage stumps for Trump … Cate Blanchett on Covid and community
A teenage Hong Kong democracy activist was charged on Thursday with secession, the first public political figure to be prosecuted under a sweeping new national security law Beijing imposed on the city.
Kyocera Corporation announced its consolidated financial results for the first half of fiscal year 2021.
A dozen Queensland schools evacuated after receiving bomb threats. Thirty schools in NSW were evacuated earlier this week after threats were emailed from eastern Europe
TV tonight: A forensic examination of Russian interference in the 2016 US electionCybersecurity ops and Russian trolls open up to Alex Gibney in a disturbing two-part documentary. Plus: More twisted parlour games from Taskmaster Greg Davies. Here’s what to watch this evening
Sanoma Corporation, Stock Exchange Release, 29 October 2020 at 08:20 EET Sanoma’s Board of Directors has decided the record date and payment date of the second dividend instalment The Board of Directors of Sanoma Corporation has in its meeting decided the record date and payment date of the second instalment of dividend for 2019, amounting to EUR 0.25 per share. The second dividend instalment shall be paid to a shareholder who is registered in the shareholders’ register of Sanoma Corporation maintained by Euroclear Finland Ltd on the dividend record date 30 October 2020. The dividend payment date for this instalment is 6 November 2020. The Annual General Meeting of Sanoma Corporation held on 25 March 2020 resolved that for 2019 a dividend of EUR 0.50 per share shall be paid in two instalments. The first instalment of EUR 0.25 per share was paid on 3 April 2020. The second instalment of EUR 0.25 per share was resolved to be paid in November 2020. Additional information Kaisa Uurasmaa, Head of Investor Relations and CSR, tel. +358 40 560 5601 Sanoma Sanoma is an innovative and agile learning and media company impacting the lives of millions every day. Our learning products and services enable teachers to develop the talents of every child to reach their full potential. We offer printed and digital course materials as well as digital learning and teaching platforms for primary, secondary and vocational education, and want to grow our business across Europe. Our Finnish media provide independent journalism and engaging entertainment also for generations to come. Our unique cross-media position offers the widest reach and tailored marketing solutions for our business partners. Today, we operate in eleven European countries and employ close to 4,500 professionals. In 2019, our net sales totalled 900m€ and our operational EBIT margin excl. PPA was 14.8%. Sanoma shares are listed on Nasdaq Helsinki. More information is available at www.sanoma.com.
The Oscar-winning star of ‘The Last King of Scotland’ talks to Alexandra Pollard about getting inside the skin of his characters, the brutality that is still occuring in America, and why a scene in his new mob drama ‘The Godfather of Harlem’ was inspired by the MeToo movement
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced financial results for the first half of fiscal year 2020 (period ended September 30, 2020).
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.